20 Jun 2016

MORNING NOTE

HUTCHMED (China) Limited (HCM:LON) | 218 0 0.0% | Mkt Cap: 1,902m

- Dr Mike Mitchell
- 3 pages

Chi-Med has announced the initiation of a Phase II expansion of the ongoing TATTON trial (NCT02143466) to evaluate the selective c-Met inhibitor savolitinib (AZD6094) in EGFR mutant non-small cell lung cancer (NSCLC) patients. The announced initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med.

Sign up to access

Get access to our full offering from over 100 providers

MORNING NOTE

HUTCHMED (China) Limited (HCM:LON) | 218 0 0.0% | Mkt Cap: 1,902m

Published: 20 Jun 2016
Author: Dr Mike Mitchell
Pages: 3

Chi-Med has announced the initiation of a Phase II expansion of the ongoing TATTON trial (NCT02143466) to evaluate the selective c-Met inhibitor savolitinib (AZD6094) in EGFR mutant non-small cell lung cancer (NSCLC) patients. The announced initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med.